Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

cg or 15mcg of sufentanil. Doses were delivered sublingually as needed to treat pain with a 20-minute minimum re-dosing interval and patients were allowed to drop out of the study at any time. Positive results were also obtained for the primary endpoint following treatment with the 15mcg dose compared to placebo using two alternate methods for imputing missing data from drop-outs: baseline observation carried forward (BOCF), p = 0.007, and last observation carried forward (LOCF), p = 0.018. Importantly, there were no events of clinically significant respiratory depression for any dosing group. Based on these positive results, AcelRx intends to further advance clinical development of ARX-01 in 2009.

"We are pleased by the wonderful clinical results of our Phase 2 post-operative acute pain study," said Thomas A. Schreck, chairman and chief executive officer of AcelRx Pharmaceuticals. "This is the culmination of a great deal of hard work by a team of efficient, dedicated people over the last two years, and is therefore very gratifying indeed. This trial has the benefit of validating Sublingual Sufentanil NanoTabs as a robust product candidate for its initial in-hospital acute pain indication, as well as providing the foundation of safety and efficacy for the other programs in our pipeline."

About ARX-01 Sublingual Sufentanil NanoTabs

Sufentanil is currently approved as an intravenous (IV) anesthetic and is also indicated for epidural administration during labor and delivery. Due to their small size, ARX-01 Sublingual Sufentanil NanoTabs are convenient, well-tolerated, have high bioavailability and provide lower peak plasma levels compared to IV administration.

About the ARX-01 Oral Patient-Controlled Analgesia System

The ARX-01 Oral Patient-Controlled Analgesia (PCA) system is based on a proprietary pre-programmed, hand-held dispenser being developed by AcelRx. The AcelRx d
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... business update. Second Quarter Financial ResultsNet sales ... increase of 50 percent compared with $5.1 million for the ... 59 percent of net sales, compared with gross profit of ...
... BETHESDA, Md., Aug. 11, 2011 The American College ... new ACMG Online Live Learning Center , which ... health care professionals. This valuable, on-demand resource brings the ... live learning offerings such as the Genetics Review Course ...
... GNVC ) today announced that its Board of ... through the adoption of a new Rights Agreement. The new ... 2011, which is the date that GenVec,s existing Rights Agreement ... in connection with the expiration of the existing Rights Agreement ...
Cached Biology Technology:Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals 2GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... wild relative of the domestic tomato, has been published ... headed by Professors Neelima Sinha and Julin Maloof at ... genome information may help breeders produce tastier, more stress-tolerant ... journal Nature Genetics , was lead by Bjrn ... UC Davis labs carried out work on the transcriptome ...
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Strategies identified to improve oral contraceptive success with obese women 2
... University of Iowa researchers have found high levels of ... Indiana Harbor and Ship Canal (IHSC) in East Chicago, Ind. ... IHSC is scheduled to be dredged in spring 2012 to ... area of southern Lake Michigan. The study, published online ...
... time when Dr. Roberto Bolli received word that he ... National Institutes of Health for one research project, five ... University of Louisville have reached the successful endpoint of ... Institute of the NIH has funded Bolli,s program project ...
... The diamondback moth, Plutella xylostella , is ... has developed resistance to many chemical and biological pesticides, ... is approximately US$1billion annually. In a new article ... , researchers from Australia have identified the genes expressed ...
Cached Biology News:Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 2Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 3Louisville researcher awarded $12.8 million NIH grant renewal for adult stem cell project 2Louisville researcher awarded $12.8 million NIH grant renewal for adult stem cell project 3Diamondback moth host-parasite interaction unraveled 2